Abstract: A method for retrieving an encrypted image of an object from a server site (22), caching it at a client site (24), and providing a decrypted image of the object to an authorized requester. When the requester is not authorized to access a decrypted image of the source data object, the encrypted image of the object cached at a client site (24) may be deleted, and/or, an authentication failure message may be sent to the server site, a security monitoring agency, the object's owner, and/or any other designated entity that can be contacted via any network accessible to the site that has detected the authentication failure.

Abstract: Compounds according to general formula (1), wherein R1 is H or CN, X1 is S, O, SO2 or CH2, X2 is O, S or CH2, X3 is NR5 or a carbonyl or thiocarbonyl group and R4 is R6R7N, R8(CH2)qOC(?O), R8(CH2)qOC(?S), R6R7NC(?O), R6R7NC(?S); R8(CH2)qC(?O), R8(CH2)qC(?S) or R8(CH2)qSO2, m is 1–3 and n is 0–4 are new. The compounds of the invention are inhibitors of dipeptidyl peptidase IV.

Abstract: The present invention provides for tricyclic compounds having the formula (I), wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Abstract: Compounds according to formula (1), wherein R1 is H or CN, X1 is S, O, SO2 or CH2, X2 is CO, CH2 or a covalent bond, Het is a nitrogen-containing heterocycle and n is 1–5 are new. The compounds of the invention are inhibitors of dipeptidyl peptidase IV.

Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Abstract: The present invention provides for thiazolopyridine-based tricyclic compounds having the formula (I), wherein R1, R2, R5, R6 and R7 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Abstract: An upstream NDC site accesses a file that is alternatively accessible through at least two downstream NDC sites. The downstream NDC sites belong to a DDS domain which is a sub-domain of a domain at the upstream NDC site. Portal files at each downstream NDC store distinct network addresses for communicating with the different downstream NDC. A DDS domain manager at the upstream NDC site retrieves and uses a first network address for establishing data conduit between the upstream NDC site and one of the downstream NDC sites. If the upstream NDC site fails to receive a response to a message, that site uses a second network address for establishing a second data conduit between the upstream NDC site and the other downstream NDC site. In another aspect, the NDC sites ensure consistency between the file and the projected image of the file cached in the upstream NDC site.

Abstract: This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ?O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ?O or ?S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n—; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.

Abstract: The present invention provides for thiazolopyridine-based tricyclic compounds having the formula (I), wherein R1, R2, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Abstract: Quinazoline and pyrido[2,3-d]pyrimidine phosphodiesterase 7 (PDE 7) inhibitors of the following formula wherein R1, R2, L, Y1, Y2, Y3 and Z are as described herein, are provided which are useful in treating T-cell mediated diseases.

Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Abstract: A hierarchical distributed search mechanism is integrated into a distributed file system. Traditional file system APIs (create, open, close, read, write, link, rename, delete, . . . ) and the over-the-wire protocols employed to project these APIs into remote client sites (CIFS, NFS, DDS, Appletalk) are extended to enable the dynamic creation of temporary directories containing links to objects identified by search engines (executing at sites “close” to “their” data) as meeting the search criteria specified by the first parameter of a search function call. The search function, derived from the standard file system API function create, is added to the file system API.

Abstract: In some embodiments, a user may select an elemental function such as read, write, or configuration from a graphical programming environment. A file may be created that instantiates functionality into a programmable hardware element to allow it to send a command across a serial protocol to peripheral interface circuitry and ultimately to peripheral chips (e.g., network chips on a CAN). The elemental node concept may be generic to any network chip because the node may contain only the general data of a packet (e.g., command type, value of data bytes, etc). The actual interface to a network chip may be handled inside the peripheral interface circuitry. The peripheral interface circuitry may have the details of the network chip in which it interfaces and may abstract details of the network chip from the target programmable hardware element through the serial protocol.

Abstract: System and method for configuring a second system in a split bridge distributed environment. A host computer system (host) includes a memory operable to store host driver software (drivers) and a CPU operable to execute the drivers. A serial bus couples the host to the second system. The host saves configuration information for the second system. The second system receives user input requesting a power down condition. The drivers enters a quiescent state, generating an indication of a power down condition. The user powers down and reconfigures the second system. The host detects a link down condition between the host and the second system, and monitors a link status between the host and second system. The user powers up the second system. The host detects a link up condition, restores second system configuration, and performs a discovery process on the second system.

Abstract: Failure of the acoustic seal in “in-the-ear” hearing aid earmolds is a principle cause of acoustic feedback. The ongoing development of smaller hearing aids with close proximity between the hearing aid microphone and receiver mandates the highest quality earmold fit. This invention relates eliminates the feedback problem by placing a soft, pliant, and durable hydrogel coating (16) on the earmold (18) The coating swells after the hearing aid is inserted and, thus, seals off any pathways for acoustic feedback. After removal at night, the earmold dries and returns to its smaller size, ready for insertion the next day.

Abstract: The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Abstract: In a network of digital computers (20), a method for facilitating access by a first digital computer (24) to a file that is stored in a local file system tree (198) of a second digital computer (22). The method includes establishing, by recursively combining hierarchical file system trees (198) that are exported from one or more NDCs (50), a hierarchical domain tree (200) that encompasses digital computers (24, 26B, 26A and 22) in the network of digital computers (20). A domain manager (212) receives policy attributes, a new type of extended attributes, and enforces policies specified therein. In a particularly preferred embodiment the policy attributes identify at least one module that must be loaded by the first digital computer (24) to extend capabilities of the first digital computer (24) used in processing a file requested from the local file system tree (198) of the second digital computer (22).

Abstract: Compounds according to general formula 1, wherein G1 is NR6R7 or a group according to general formula 3 and G2 NR24R25 or a fused polycyclic group are novel. They are selective and potent oxytocin agonists. Pharmaceutical compositions of such compounds are useful in the treatment of, inter alia, erectile dysfunction.

Abstract: Compounds according to general formula (1) and their pharmaceutically acceptable salts are new. The compounds are inhibitors of dipeptidyl peptidase IV or prodrugs thereof, and are useful in the treatment of, inter alia type 2 diabetes and impaired glucose tolerance. In the general formula A is F or H, one of R1A and R1B is H or CN and the other H, R2 is H, alkyl, aralkyl or R5, R3 is H or a substituted aminoalkyl group and R4 is H or acyl.

Abstract: Compounds according to formula (1), wherein R1 is H or CN, X1 is S, O, SO2 or CH2, X2 is CO, CH2 or a covalent bond, Het is a nitrogen-containing heterocycle and n is 1-5 are new. The compounds of the invention are inhibitors of dipeptidyl peptidase IV. Pharmaceutical compositions of the compounds of the invention, or pharmaceutically acceptable salts thereof, are useful in the treatment of, inter alia, type 2 diabetes.